Jason Grenfell-Gardner appointed as CEO of IGI Laboratories, Inc.
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based
pharmaceutical company, today announced that Jason Grenfell-Gardner has
been appointed President and Chief Executive Officer of IGI
Laboratories, Inc. effective July 30, 2012.
Ms. Joyce Erony, Chairman of the Company, commented, "On behalf of the
Board of Directors, I would like to express my gratitude for the
dedication and leadership provided by Charlie Moore during his tenure at
IGI as President and Chief Executive Officer. I would also like to take
this opportunity to congratulate Jason whose comprehensive experience in
the pharmaceutical market and the commercialization of products makes
Jason the appropriate leader to establish the IGI brand and portfolio of
generic topical prescription drug products in the marketplace."
Jason Grenfell-Gardner brings significant experience in the
pharmaceutical industry, with a particular focus on generics. Most
recently, Jason was the Senior Vice President of Sales and Marketing for
West-Ward Pharmaceuticals, the US Subsidiary of Hikma Pharmaceuticals.
Jason has served in that role since 2008. Jason was an integral part of
the senior management team which grew the business from just over $100
million in 2008 to over $300 million in 2011. He solidified West-Ward's
presence in the sterile injectable space through the acquisition of
Baxter International, Inc.'s multisource injectable business in 2011. He
originally joined Hikma Pharmaceuticals to lead its initial public
offering in 2004, and later headed their business development efforts.
Prior to 2004, Jason gained a number of years of investment banking
experience in Central and Eastern Europe with Trigon Capital, and served
as Chairman of the Board of Sanitas Pharmaceuticals. Jason has an MA in
Economics from the University of St. Andrews in Scotland, and an MBA
from INSEAD, where he studied in both France and Singapore.
About IGI Laboratories, Inc.
IGI Laboratories is a developer and manufacturer of topical formulations
for the pharmaceutical, OTC, and cosmetic markets.
IGI Laboratories, Inc. "Safe Harbor" Statement under the Private
Securities Litigation Reform Act of 1995. This press release includes
certain "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, plans, objectives,
expectations and intentions, and other statements contained in this
press release that are not historical facts and statements identified by
words such as "will," "possible," "one time," "provides an opportunity,"
"continue" or words of similar meaning. These statements are based on
our current beliefs or expectations and are inherently subject to
various risks and uncertainties, including those set forth under the
caption "Risk Factors" in IGI Laboratories, Inc.'s most recent Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the
Securities and Exchange Commission. Actual results may differ materially
from these expectations due to changes in global political, economic,
business, competitive, market and regulatory factors or IGI
Laboratories, Inc.'s ability to implement business strategies. IGI
Laboratories, Inc. does not undertake any obligation to update any
forward-looking statements contained in this document as a result of new
information, future events or otherwise.
IGI Laboratories, Inc.
Jenniffer Collins, 856-697-4379